Shigehiro Koganemaru - Department of Experimental Therapeutics, National Cancer Center Hospital East

基本信息

浏览量：0

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 31 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

Abstract 5760: Intra-tissue Quantitative Analysis Using LC/MS Will Determine the Mechanisms of Interstitial Pneumonia Induced by Antibody-Drug Conjugates

Shigehiro Koganemaru,Hirobumi Fuchigami, Chihiro Morizono, Hiroko Shinohara,Yasutoshi Kuboki,Keiji Furuuchi,Toshimitsu Uenaka,Toshihiko Doi,Masahiro Yasunaga

CANCER RESEARCHno. 6 (2024)

引用0浏览0引用

Table ST2 from Safety, Tolerability, and Pharmacokinetics of TAK-931, a Cell Division Cycle 7 Inhibitor, in Patients with Advanced Solid Tumors: A Phase I First-in-Human Study

Yasutoshi Kuboki,Toshio Shimizu,Kan Yonemori,Takashi Kojima,Shunsuke Kondo,Shigehiro Koganemaru,Satoru Iwasa,Kenichi Harano,Takafumi Koyama,Vickie Lu,Xiaofei Zhou,Huifeng Niu,Tomoko Yanai, Ignacio Garcia-Ribas,Toshihiko Doi,Noboru Yamamoto

openalex（2023）

引用0浏览0引用

Data from U3-1402, a Novel HER3-Targeting Antibody–Drug Conjugate, for the Treatment of Colorectal Cancer

Shigehiro Koganemaru,Yasutoshi Kuboki,Yoshikatsu Koga,Takashi Kojima,Mayumi Yamauchi,Naoyuki Maeda,Takashi Kagari,Kenji Hirotani,Masahiro Yasunaga,Yasuhiro Matsumura,Toshihiko Doi

crossref（2023）

引用0浏览0引用

Quantitative Analysis of the Concentration of Trifluridine in Tumor Hypoxic Regions Using a Novel Platform Combining Functional Endoscopy and Mass Spectrometry

Shigehiro Koganemaru,Hirobumi Fuchigami,Hiroki Yamashita, Chihiro Morizono,Hironori Sunakawa,Akihito Kawazoe,Yoshiaki Nakamura,Yasutoshi Kuboki,Kohei Shitara,Tomonori Yano,Toshihiko Doi,Masahiro Yasunaga

Clinical Pharmacology &amp Therapeuticsno. 1 (2023): 62-70

引用0浏览0WOS引用

Supplementary Methods SM1 from Safety, Tolerability, and Pharmacokinetics of TAK-931, a Cell Division Cycle 7 Inhibitor, in Patients with Advanced Solid Tumors: A Phase I First-in-Human Study

Yasutoshi Kuboki,Toshio Shimizu,Kan Yonemori, Takashi Kojima,Shunsuke Kondo,Shigehiro Koganemaru,Satoru Iwasa,Kenichi Harano,Takafumi Koyama,Vickie Lu, Xiaofei Zhou,Huifeng Niu,Tomoko Yanai, Ignacio Garcia-Ribas,Toshihiko Doi,Noboru Yamamoto

crossref（2023）

引用0浏览0引用

Figure S4 from U3-1402, a Novel HER3-Targeting Antibody–Drug Conjugate, for the Treatment of Colorectal Cancer

Shigehiro Koganemaru,Yasutoshi Kuboki,Yoshikatsu Koga,Takashi Kojima,Mayumi Yamauchi,Naoyuki Maeda,Takashi Kagari,Kenji Hirotani,Masahiro Yasunaga,Yasuhiro Matsumura,Toshihiko Doi

openalex（2023）

引用0浏览0引用

Special Issue: Evaluation of the Antitumor Mechanism of Armed Antibodies

Yoshikatsu Koga,Hiroki Takashima,Shigehiro Koganemaru

PHARMACEUTICALS（2023）

引用0浏览0WOS引用

Figure SF4 from Safety, Tolerability, and Pharmacokinetics of TAK-931, a Cell Division Cycle 7 Inhibitor, in Patients with Advanced Solid Tumors: A Phase I First-in-Human Study

Yasutoshi Kuboki,Toshio Shimizu,Kan Yonemori,Takashi Kojima,Shunsuke Kondo,Shigehiro Koganemaru, Satoru Iwasa, Kenichi Harano,Takafumi Koyama,Vickie Lu,Xiaofei Zhou,Huifeng Niu,Tomoko Yanai, Ignacio Garcia-Ribas,Toshihiko Doi,Noboru Yamamoto

openalex（2023）

引用0浏览0引用

Figure S3 from U3-1402, a Novel HER3-Targeting Antibody–Drug Conjugate, for the Treatment of Colorectal Cancer

Shigehiro Koganemaru,Yasutoshi Kuboki,Yoshikatsu Koga,Takashi Kojima,Mayumi Yamauchi,Naoyuki Maeda,Takashi Kagari,Kenji Hirotani,Masahiro Yasunaga,Yasuhiro Matsumura,Toshihiko Doi

openalex（2023）

引用0浏览0引用

Figure SF3 from Safety, Tolerability, and Pharmacokinetics of TAK-931, a Cell Division Cycle 7 Inhibitor, in Patients with Advanced Solid Tumors: A Phase I First-in-Human Study

Yasutoshi Kuboki,Toshio Shimizu,Kan Yonemori,Takashi Kojima,Shunsuke Kondo,Shigehiro Koganemaru,Satoru Iwasa,Kenichi Harano,Takafumi Koyama, Vickie Lu, Xiaofei Zhou,Huifeng Niu,Tomoko Yanai, Ignacio Garcia-Ribas, Toshihiko Doi,Noboru Yamamoto

openalex（2023）

引用0浏览0引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn